Invivyd, Inc. (IVVD)Healthcare | Biotechnology | New Haven, United States | NasdaqGM
0.79 USD
+0.00
(0.523%)
⇧
(July 13, 2026, 4 p.m.
EDT)
After hours: 0.79 +0.00 (0.317%) ⇧ (July 13, 2026, 6:41 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 6:57 a.m. EDT
The investment case for Invivyd is currently defined by a severe disconnect between optimistic analyst targets and the brutal reality of its financial performance. While analysts project a tenfold increase to $10.00, the company is burning through cash at an alarming rate, reporting negative free cash flow and operating cash flow, alongside a triple-digit decline in stock price over the last three years. The market has correctly identified this as a value trap; despite the 'strong buy' recommendation, the fundamentals—negative earnings, shrinking revenue growth, and a deteriorating balance sheet—do not support a premium valuation. The options market confirms this pessimism, with traders aggressively buying puts to hedge against further collapse rather than betting on a rebound. Until the company demonstrates a clear path to profitability and stabilizes its cash burn, the risk of permanent capital loss outweighs the speculative upside. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.344177 |
| AutoETS | 0.345187 |
| AutoTheta | 0.345260 |
| AutoARIMA | 0.345942 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 27% |
| H-stat | 5.81 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.274 |
| Excess Kurtosis | -0.56 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 4.248 |
| Revenue per Share | 0.254 |
| Market Cap | 232,003,376 |
| Forward P/E | -1.36 |
| Beta | 0.67 |
| Profit Margins | -138.90% |
| Previous Name | Adagio Therapeutics, Inc. |
| Website | https://www.invivyd.com |
As of July 11, 2026, 6:57 a.m. EDT: Speculators are overwhelmingly positioning for downside protection rather than upside participation. Put open interest dominates across nearly all expirations, with massive concentration in strikes significantly below the current price (e.g., deep OTM puts at $0.50 and ATM puts at $1.00). Call activity is sparse and concentrated in very distant strikes ($5.00), suggesting a speculative 'lottery ticket' mentality rather than a genuine belief in near-term recovery. Implied volatility is elevated on downside strikes, indicating the market prices in a high probability of further decline.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.07702887 |
| Address1 | 209 Church Street |
| All Time High | 78.82 |
| All Time Low | 0.355 |
| Ask | 1.0 |
| Ask Size | 2 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 6,408,030 |
| Average Daily Volume3 Month | 4,148,081 |
| Average Volume | 4,148,081 |
| Average Volume10Days | 6,408,030 |
| Beta | 0.671 |
| Bid | 0.581 |
| Bid Size | 2 |
| Book Value | 0.718 |
| City | New Haven |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.7875 |
| Current Ratio | 6.473 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 0.8359 |
| Day Low | 0.7701 |
| Debt To Equity | 4.248 |
| Display Name | Invivyd |
| Earnings Call Timestamp End | 1,778,761,800 |
| Earnings Call Timestamp Start | 1,778,761,800 |
| Earnings Timestamp | 1,778,761,800 |
| Earnings Timestamp End | 1,786,624,200 |
| Earnings Timestamp Start | 1,786,624,200 |
| Ebitda | -81,157,000 |
| Ebitda Margins | -1.4527099 |
| Enterprise To Ebitda | -0.696 |
| Enterprise To Revenue | 1.011 |
| Enterprise Value | 56,476,368 |
| Eps Current Year | -0.53 |
| Eps Forward | -0.58 |
| Eps Trailing Twelve Months | -0.29 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.08814 |
| Fifty Day Average Change | -0.30064 |
| Fifty Day Average Change Percent | -0.27628797 |
| Fifty Two Week Change Percent | 7.702887 |
| Fifty Two Week High | 3.07 |
| Fifty Two Week High Change | -2.2824998 |
| Fifty Two Week High Change Percent | -0.7434853 |
| Fifty Two Week Low | 0.483 |
| Fifty Two Week Low Change | 0.3045 |
| Fifty Two Week Low Change Percent | 0.6304348 |
| Fifty Two Week Range | 0.483 - 3.07 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,628,256,600,000 |
| Float Shares | 214,303,353 |
| Forward Eps | -0.58 |
| Forward P E | -1.3577588 |
| Free Cashflow | -50,099,752 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 122 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.92938006 |
| Gross Profits | 51,921,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.070700005 |
| Held Percent Institutions | 0.83893996 |
| Implied Shares Outstanding | 294,607,452 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand. It also develops VYD2311, a monoclonal antibody, which is in Phase III clinical trial for the prevention and treatment of SARS-CoV-2 virus; and VBY329, a monoclonal antibody, which is in pre-clinical trial stage for the prevention and treatment of respiratory syncytial virus and measles in neonates, infants, and children. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in New Haven, Connecticut. |
| Long Name | Invivyd, Inc. |
| Market | us_market |
| Market Cap | 232,003,376 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_677282690 |
| Most Recent Quarter | 1,774,915,200 |
| Name Change Date | 2,026-07-13 |
| Net Income To Common | -77,600,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 231,679,300 |
| Number Of Analyst Opinions | 3 |
| Open | 0.8095 |
| Operating Cashflow | -78,718,000 |
| Operating Margins | -3.13853 |
| Payout Ratio | 0.0 |
| Phone | 781 819 0080 |
| Post Market Change | 0.0024999976 |
| Post Market Change Percent | 0.31746 |
| Post Market Price | 0.79 |
| Post Market Time | 1,783,982,516 |
| Prev Name | Adagio Therapeutics, Inc. |
| Previous Close | 0.7834 |
| Price Eps Current Year | -1.4858491 |
| Price Hint | 4 |
| Price To Book | 1.0967968 |
| Price To Sales Trailing12 Months | 4.1528544 |
| Profit Margins | -1.3890401 |
| Quick Ratio | 6.203 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | 0.00410002 |
| Regular Market Change Percent | 0.523363 |
| Regular Market Day High | 0.8359 |
| Regular Market Day Low | 0.7701 |
| Regular Market Day Range | 0.7701 - 0.8359 |
| Regular Market Open | 0.8095 |
| Regular Market Previous Close | 0.7834 |
| Regular Market Price | 0.7875 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 2,450,939 |
| Return On Assets | -0.29587 |
| Return On Equity | -0.60342 |
| Revenue Growth | 0.216 |
| Revenue Per Share | 0.254 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 294,607,452 |
| Shares Percent Shares Out | 0.093100004 |
| Shares Short | 27,441,668 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 30,932,931 |
| Short Name | Invivyd, Inc. |
| Short Percent Of Float | 0.1029 |
| Short Ratio | 4.06 |
| Source Interval | 15 |
| State | CT |
| Symbol | IVVD |
| Target High Price | 10.0 |
| Target Low Price | 10.0 |
| Target Mean Price | 10.0 |
| Target Median Price | 10.0 |
| Total Cash | 184,152,992 |
| Total Cash Per Share | 0.625 |
| Total Debt | 8,626,000 |
| Total Revenue | 55,866,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.29 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.67831 |
| Two Hundred Day Average Change | -0.89081 |
| Two Hundred Day Average Change Percent | -0.530778 |
| Type Disp | Equity |
| Volume | 2,450,939 |
| Website | https://www.invivyd.com |
| Zip | 6,510 |